Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Korsana Biosciences, Inc.CYCN · Entity 7698 | Chief Financial Officer | January 20, 2022 | January 24, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Korsana Biosciences, Inc.
Report date January 20, 2022 · Filed January 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 · Expires 2032-01-20 | Direct | 135,000 |
Reported balance
After 2022-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-20 · Grant · Acquired 135,000 · Balance 135,000 F1: The stock option vests and becomes exercisable as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 20, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 20, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 20, 2022 Filed Jan 24, 2022 16:43 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001140361-22-002456 · form4.xml · derivative · entry 1 Gjino Anjeza · CIK 0001839068 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2032-01-20 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 20, 2022. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 21:31 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001140361-21-041209 · form4.xml · derivative · entry 1 Gjino Anjeza · CIK 0001839068 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-12-09 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 2.08333% of the shares of Common Stock on each monthly anniversary of December 9, 2021. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:23 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | SaleCommon Stock | 1,824 | $4.00 | $7,296.00 |
DisclosureSEC source: 0001140361-21-006649 · form4.xml · nonDerivative · entry 1 Gjino Anjeza · CIK 0001839068 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,599 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on April 1, 2019. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.80 to $4.00, inclusive. The reporting person will provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.